Position in JNJ
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$6,069,883
+$4,667,042 QoQ
Shares Held
23,900
+316.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.34%
of 13F equity value
Holder Rank
#1,474
of 4,664 holders
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Catalyst Funds Management Pty Ltd holds $79,371,078 across 9 Drug Manufacturers - General names. JNJ ranks #4 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
38,081 | $45,675,497 | |
| 2 | ABBV |
AbbVie Inc.
|
47,019 | $11,831,861 | |
| 3 | AZN |
Astrazeneca PLC
|
44,699 | $8,475,824 | |
| 4 | JNJ |
Johnson & Johnson
This page
|
23,900 | $6,069,883 | |
| 5 | MRK |
Merck & Co., Inc.
|
23,750 | $3,051,875 | |
| 6 | BIIB |
Biogen Inc.
|
11,400 | $2,463,084 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
7,400 | $934,916 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
8,782 | $506,018 |
All Filings in JNJ
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,069,883 | 23,900 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $1,402,841 | 5,739 | Shares | Sole | 2026-05-11 | |
| 2025-09-30 | $1,464,818 | 7,900 | Shares | Sole | 2025-11-12 | |
| 2025-03-31 | $895,536 | 5,400 | Shares | Sole | 2025-05-14 | |
| 2024-09-30 | $1,264,068 | 7,800 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $102,312 | 700 | Shares | Sole | 2024-12-18 | |
| No filing history on record for this holder in this stock. | ||||||